Hansa Medical in brief

Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The Company’s lead product, imlifidase, is a proprietary, antibody-degrading enzyme for enabling kidney transplantation in highly sensitized patients. Imlifidase is currently under potential marketing authorization by EMA and has potential for further development in other solid organ transplantation and acute autoimmune indications. Hansa also has a strong pipeline of preclinical projects, including NiceR, through which the Company is developing novel immunoglobulin-cleaving enzymes for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden, and its shares are listed on NASDAQ Stockholm (HNSA).

Key facts

  • Innovative and promising pipeline
    • Imlifidase – candidate drug in several Phase 2 trials in kidney transplantation
    • NiceR - Novel immunoglobulin cleaving enzymes for Repeat dosing
    • EnzE - Enzyme based antibody Enhancement
  • First-rate global scientific network within transplantation and immunology
  • Board of Directors with long pharma and biotech experience
  • Small and innovative team (Approx. 60 employees)
  • Based in Lund, Sweden
  • Listed on NASDAQ Stockholm (ticker: HNSA)
  • 759 MSEK in cash and short term investments, March 31, 2019